Pretomanid (Dovprela)

Synonym(s): PA-824

Class: Nitroimidazole

Spectrum of activity:	Gram-positive
Details of activity:	Inhibits the synthesis of protein and cell wall lipid
Combined with other compounds:	Yes
Description:	Nitroimidazopyran derivative. Developed for the treatment of multidrug-resistant Mycobacterium tuberculosis in combination with bedaquiline and linezolid.
Institute where first reported:	Mylan Ireland Limited
Year first mentioned:	2000
Highest developmental phase:	Approved by FDA in 2019
Development status:	Approved

Chemical structure(s):
Canonical SMILES:	C1=C(C=CC(=C1)OC(F)(F)F)CO[C@H]2CN3C=C(N=C3OC2)[N+](=O)[O-]
Isomeric SMILES:	C1[C@@H](COC2=NC(=CN21)[N+](=O)[O-])OCC3=CC=C(C=C3)OC(F)(F)F
InChI:	InChI=1S/C14H12F3N3O5/c15-14(16,17)25-10-3-1-9(2-4-10)7-23-11-5-19-6-12(20(21)22)18-13(19)24-8-11/h1-4,6,11H,5,7-8H2/t11-/m0/s1
InChI Key:	ZLHZLMOSPGACSZ-NSHDSACASA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/456199

External links:
Guide to Pharmacology:	pretomanid
Main Source:	https://pubmed.ncbi.nlm.nih.gov/36053513/
Citations:	https://linkinghub.elsevier.com/retrieve/pii/S1198-743X(21)00464-X https://www.nature.com/articles/35016103 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2717523/